{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:47:01Z","timestamp":1778662021626,"version":"3.51.4"},"reference-count":227,"publisher":"Elsevier","isbn-type":[{"value":"9780128120743","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.acc.2017.01.004","type":"book-chapter","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T04:46:18Z","timestamp":1489812378000},"page":"135-192","source":"Crossref","is-referenced-by-count":17,"title":["Human Papillomavirus and Its Testing Assays, Cervical Cancer Screening, and Vaccination"],"prefix":"10.1016","member":"78","reference":[{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/0022034509333446","article-title":"Replication and assembly of human papillomaviruses","volume":"88","author":"Conway","year":"2009","journal-title":"J. Dent. Res."},{"issue":"8","key":"10.1016\/bs.acc.2017.01.004_bb0010","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1128\/JVI.77.8.4818-4826.2003","article-title":"Interactions between papillomavirus L1 and L2 capsid proteins","volume":"77","author":"Finnen","year":"2003","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1586\/erv.12.151","article-title":"Virus-like particles for the prevention of human papillomavirus-associated malignancies","volume":"12","author":"Wang","year":"2013","journal-title":"Expert Rev. Vaccines"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0020","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/JVI.73.3.1835-1845.1999","article-title":"DNA replication of human papillomavirus type 31 is modulated by elements of the upstream regulatory region that lie 5\u02b9 of the minimal origin","volume":"73","author":"Hubert","year":"1999","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/nar\/18.3.465","article-title":"Transcriptional activation of human papillomavirus 16 by nuclear factor I, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers","volume":"18","author":"Chong","year":"1990","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/bs.acc.2017.01.004_bb0030","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1093\/nar\/17.9.3519","article-title":"Clusters of nuclear factor I binding sites identify enhancers of several papillomaviruses but alone are not sufficient for enhancer function","volume":"17","author":"Gloss","year":"1989","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/bs.acc.2017.01.004_bb0035","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1128\/JVI.07239-11","article-title":"Differentiation-dependent changes in levels of C\/EBPbeta repressors and activators regulate human papillomavirus type 31 late gene expression","volume":"86","author":"Gunasekharan","year":"2012","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1006\/viro.1997.8771","article-title":"The 5\u02b9 region of the human papillomavirus type 31 upstream regulatory region acts as an enhancer which augments viral early expression through the action of YY1","volume":"237","author":"Kanaya","year":"1997","journal-title":"Virology"},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb0045","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1128\/jvi.70.10.6529-6539.1996","article-title":"YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity","volume":"70","author":"O'Connor","year":"1996","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1128\/JVI.72.2.1071-1077.1998","article-title":"Differential requirements for conserved E2 binding sites in the life cycle of oncogenic human papillomavirus type 31","volume":"72","author":"Stubenrauch","year":"1998","journal-title":"J. Virol."},{"issue":"Pt. 8","key":"10.1016\/bs.acc.2017.01.004_bb0055","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1099\/0022-1317-78-8-1963","article-title":"Regulation of human papillomavirus type 16 DNA replication by E2, glucocorticoid hormone and epidermal growth factor","volume":"78","author":"Piccini","year":"1997","journal-title":"J. Gen. Virol."},{"issue":"11","key":"10.1016\/bs.acc.2017.01.004_bb0060","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1073\/pnas.90.11.5086","article-title":"The E1 protein of bovine papilloma virus 1 is an ATP-dependent DNA helicase","volume":"90","author":"Yang","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"26","key":"10.1016\/bs.acc.2017.01.004_bb0065","doi-asserted-by":"crossref","first-page":"23689","DOI":"10.1074\/jbc.M101861200","article-title":"Mechanism and requirements for bovine papillomavirus, type 1, E1 initiator complex assembly promoted by the E2 transcription factor bound to distal sites","volume":"276","author":"Sanders","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb0070","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1128\/JVI.07003-11","article-title":"Inhibition of human papillomavirus DNA replication by an E1-derived p80\/UAF1-binding peptide","volume":"86","author":"Lehoux","year":"2012","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0075","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1128\/jvi.66.6.3941-3945.1992","article-title":"Mechanism of action of the papillomavirus E2 repressor: repression in the absence of DNA binding","volume":"66","author":"Barsoum","year":"1992","journal-title":"J. Virol."},{"issue":"22","key":"10.1016\/bs.acc.2017.01.004_bb0080","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1128\/JVI.01127-06","article-title":"Characterization of the functional activities of the bovine papillomavirus type 1 E2 protein single-chain heterodimers","volume":"80","author":"Kurg","year":"2006","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0042-6822(87)90482-X","article-title":"A human papilloma virus type 11 transcript encoding an E1\u2013E4 protein","volume":"159","author":"Nasseri","year":"1987","journal-title":"Virology"},{"issue":"8","key":"10.1016\/bs.acc.2017.01.004_bb0090","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1128\/JVI.02063-08","article-title":"Phosphorylation of the human papillomavirus type 16 E1\u02c6E4 protein at T57 by ERK triggers a structural change that enhances keratin binding and protein stability","volume":"83","author":"Wang","year":"2009","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0095","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/j.1460-2075.1988.tb02881.x","article-title":"Analysis of HPV-1 E4 gene expression using epitope-defined antibodies","volume":"7","author":"Doorbar","year":"1988","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2006.02.024","article-title":"HPV16 E1\u2013E4 protein is phosphorylated by Cdk2\/cyclin A and relocalizes this complex to the cytoplasm","volume":"349","author":"Davy","year":"2006","journal-title":"Virology"},{"issue":"18","key":"10.1016\/bs.acc.2017.01.004_bb0105","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1128\/JVI.01080-08","article-title":"Identification of an arginine-rich motif in human papillomavirus type 1 E1\u02c6E4 protein necessary for E4-mediated inhibition of cellular DNA synthesis in vitro and in cells","volume":"82","author":"Roberts","year":"2008","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2011.01.007","volume":"412","author":"Knight","year":"2011","journal-title":"Virology"},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049974","article-title":"E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease","volume":"7","author":"Griffin","year":"2012","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/bs.acc.2017.01.004_bb0120","doi-asserted-by":"crossref","first-page":"8196","DOI":"10.1128\/JVI.00509-08","article-title":"Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1\u2227E4 protein and provides a molecular basis for its accumulation","volume":"82","author":"McIntosh","year":"2008","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-009-0412-8","article-title":"The biological properties of E6 and E7 oncoproteins from human papillomaviruses","volume":"40","author":"Ghittoni","year":"2010","journal-title":"Virus Genes"},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fvl.14.99","article-title":"Human papillomavirus E5 oncoprotein: function and potential target for antiviral therapeutics","volume":"10","author":"M\u00fcller","year":"2015","journal-title":"Futur. Virol."},{"issue":"16","key":"10.1016\/bs.acc.2017.01.004_bb0135","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.1128\/JVI.00670-11","article-title":"Construction of a full transcription map of human papillomavirus type 18 during productive viral infection","volume":"85","author":"Wang","year":"2011","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/bs.acc.2017.01.004_bb0140","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1128\/JVI.02726-07","article-title":"Arrangement of L2 within the papillomavirus capsid","volume":"82","author":"Buck","year":"2008","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0145","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1128\/cdli.3.6.733-739.1996","article-title":"Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein","volume":"3","author":"Iyengar","year":"1996","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"21","key":"10.1016\/bs.acc.2017.01.004_bb0150","doi-asserted-by":"crossref","first-page":"11426","DOI":"10.1128\/JVI.01721-13","article-title":"Multiple heparan sulfate binding site engagements are required for the infectious entry of human papillomavirus type 16","volume":"87","author":"Richards","year":"2013","journal-title":"J. Virol."},{"issue":"20","key":"10.1016\/bs.acc.2017.01.004_bb0155","doi-asserted-by":"crossref","first-page":"10442","DOI":"10.1128\/JVI.01588-15","article-title":"Topography of the human papillomavirus minor capsid protein L2 during vesicular trafficking of infectious entry","volume":"89","author":"DiGiuseppe","year":"2015","journal-title":"J. Virol."},{"issue":"14","key":"10.1016\/bs.acc.2017.01.004_bb0160","doi-asserted-by":"crossref","first-page":"12546","DOI":"10.1074\/jbc.M208691200","article-title":"Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection","volume":"278","author":"Yang","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.virol.2009.08.034","article-title":"Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions","volume":"394","author":"Kondo","year":"2009","journal-title":"Virology"},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0170","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.virol.2011.11.007","article-title":"The high risk HPV16 L2 minor capsid protein has multiple transport signals that mediate its nucleocytoplasmic traffic","volume":"422","author":"Mamoor","year":"2012","journal-title":"Virology"},{"key":"10.1016\/bs.acc.2017.01.004_bb0175","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fmicb.2012.00152","article-title":"Productive lifecycle of human papillomaviruses that depends upon squamous epithelial differentiation","volume":"3","author":"Kajitani","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1743-422X-7-2","article-title":"Cellular receptor binding and entry of human papillomavirus","volume":"7","author":"Letian","year":"2010","journal-title":"Virol. J."},{"key":"10.1016\/bs.acc.2017.01.004_bb0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0065-3527(08)00404-1","article-title":"Replication and partitioning of papillomavirus genomes","volume":"72","author":"McBride","year":"2008","journal-title":"Adv. Virus Res."},{"issue":"21","key":"10.1016\/bs.acc.2017.01.004_bb0190","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","article-title":"Mechanisms of human papillomavirus-induced oncogenesis","volume":"78","author":"M\u00fcnger","year":"2004","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb0195","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1128\/jvi.71.7.5161-5172.1997","article-title":"Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b","volume":"71","author":"Ozbun","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0200","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.virol.2014.12.028","article-title":"International standardization and classification of human papillomavirus types","volume":"476","author":"Bzhalava","year":"2015","journal-title":"Virology"},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1590\/S0365-05962011000200014","article-title":"Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations","volume":"86","author":"Leto","year":"2011","journal-title":"An. Bras. Dermatol."},{"issue":"13","key":"10.1016\/bs.acc.2017.01.004_bb0210","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1200\/JCO.2010.28.2186","article-title":"Human papillomaviruses as therapeutic targets in human cancer","volume":"29","author":"Hellner","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0215","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.7314\/APJCP.2015.16.6.2145","article-title":"Multifaceted usage of HPV related tests and products in the management of cervical cancer\u2014a review","volume":"16","author":"Nalliah","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099114","article-title":"Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia","volume":"9","author":"Omland","year":"2014","journal-title":"PLoS One"},{"issue":"Suppl. 2","key":"10.1016\/bs.acc.2017.01.004_bb0225","first-page":"S47","article-title":"Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus","volume":"17","author":"Bhatia","year":"2013","journal-title":"J. Cutan. Med. Surg."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"de Villiers","year":"2004","journal-title":"Virology"},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernard","year":"2010","journal-title":"Virology"},{"key":"10.1016\/bs.acc.2017.01.004_bb0240","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1479-5876-8-105","article-title":"HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future","volume":"8","author":"Mariani","year":"2010","journal-title":"J. Transl. Med."},{"issue":"13","key":"10.1016\/bs.acc.2017.01.004_bb0245","first-page":"3478","article-title":"Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells","volume":"63","author":"Fausch","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/bs.acc.2017.01.004_bb0250","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1479-5876-12-44","article-title":"Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort","volume":"12","author":"Koskimaa","year":"2014","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0255","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0260","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.bbamcr.2013.06.010","article-title":"Cell death by cornification","volume":"1833","author":"Eckhart","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0265","first-page":"266","article-title":"Immune responses to human papillomaviruses","volume":"130","author":"Stanley","year":"2009","journal-title":"Indian J. Med. Res."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc700","article-title":"Immune evasion in human papillomavirus-associated cervical cancer","volume":"2","author":"Tindle","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2017.01.004_bb0275","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.vaccine.2005.09.002","article-title":"Immune responses to human papillomavirus","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0280","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.167.1.497","article-title":"Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells","volume":"167","author":"Lee","year":"2001","journal-title":"J. Immunol."},{"issue":"22","key":"10.1016\/bs.acc.2017.01.004_bb0285","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1128\/JVI.02151-15","article-title":"Downregulation of toll-like receptor 9 expression by beta human papillomavirus 38 and implications for cell cycle control","volume":"89","author":"Pacini","year":"2015","journal-title":"J. Virol."},{"issue":"23","key":"10.1016\/bs.acc.2017.01.004_bb0290","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1128\/JVI.79.23.14852-14862.2005","article-title":"Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6\/E7 is related to reduced macrophage inflammatory protein-3alpha production","volume":"79","author":"Guess","year":"2005","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0295","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0042-6822(03)00103-X","article-title":"The E5 protein of human papillomavirus type 16 perturbs MHC class II antigen maturation in human foreskin keratinocytes treated with interferon-gamma","volume":"310","author":"Zhang","year":"2003","journal-title":"Virology"},{"key":"10.1016\/bs.acc.2017.01.004_bb0300","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/1874357901206010241","article-title":"The immune response to papillomavirus during infection persistence and regression","volume":"6","author":"Hibma","year":"2012","journal-title":"Open Virol. J."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0305","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/jcp.44.12.969","article-title":"Current views on cervical intraepithelial neoplasia","volume":"44","author":"Anderson","year":"1991","journal-title":"J. Clin. Pathol."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0310","first-page":"203","article-title":"Robbins\u2019 basic pathology","volume":"118","author":"Kumar","year":"1994","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/bs.acc.2017.01.004_bb0315","series-title":"Blaustein's Pathology of the Female Genital Tract","first-page":"193","article-title":"Precancerous lesions of the cervix","author":"Wright","year":"2011"},{"key":"10.1016\/bs.acc.2017.01.004_bb0320","series-title":"The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes","author":"Nayar","year":"2015"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0325","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/0971-5851.92808","article-title":"An overview of prevention and early detection of cervical cancers","volume":"32","author":"Mishra","year":"2011","journal-title":"Indian J. Med. Paediatr. Oncol."},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0330","first-page":"483","article-title":"Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide","volume":"11","author":"Kadish","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/bs.acc.2017.01.004_bb0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1750-9378-2-15","article-title":"Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women","volume":"2","author":"Insinga","year":"2007","journal-title":"Infect. Agent Cancer"},{"issue":"7587","key":"10.1016\/bs.acc.2017.01.004_bb0340","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nature16481","article-title":"Structure of the E6\/E6AP\/p53 complex required for HPV-mediated degradation of p53","volume":"529","author":"Martinez-Zapien","year":"2016","journal-title":"Nature"},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0345","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.cdd.4401678","article-title":"The human papillomavirus 16 E6 protein can either protect or further sensitize cells to TNF: effect of dose","volume":"12","author":"Filippova","year":"2005","journal-title":"Cell Death Differ."},{"issue":"23","key":"10.1016\/bs.acc.2017.01.004_bb0350","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1128\/JVI.76.23.12162-12172.2002","article-title":"The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms","volume":"76","author":"Kabsch","year":"2002","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/bs.acc.2017.01.004_bb0355","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/sj.cdd.4401886","article-title":"Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis","volume":"13","author":"Garnett","year":"2006","journal-title":"Cell Death Differ."},{"issue":"21","key":"10.1016\/bs.acc.2017.01.004_bb0360","doi-asserted-by":"crossref","first-page":"10408","DOI":"10.1128\/JVI.00902-08","article-title":"E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation","volume":"82","author":"Underbrink","year":"2008","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb0365","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1073\/pnas.89.10.4549","article-title":"Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product","volume":"89","author":"Chellappan","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"19","key":"10.1016\/bs.acc.2017.01.004_bb0370","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1101\/gad.9.19.2335","article-title":"Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes","volume":"9","author":"Cheng","year":"1995","journal-title":"Genes Dev."},{"issue":"19","key":"10.1016\/bs.acc.2017.01.004_bb0375","doi-asserted-by":"crossref","first-page":"10566","DOI":"10.1128\/JVI.77.19.10566-10574.2003","article-title":"Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7","volume":"77","author":"He","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0380","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1074\/jbc.M508455200","article-title":"Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor","volume":"281","author":"Liu","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0385","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaci.2010.11.005","article-title":"TNF-like weak inducer of apoptosis (TWEAK) and TNF-alpha cooperate in the induction of keratinocyte apoptosis","volume":"127","author":"Zimmermann","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0390","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/jvi.69.5.2989-2997.1995","article-title":"Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells","volume":"69","author":"Jeon","year":"1995","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0395","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1128\/JVI.02149-08","article-title":"Abrogation of the postmitotic checkpoint contributes to polyploidization in human papillomavirus E7-expressing cells","volume":"83","author":"Heilman","year":"2009","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0400","doi-asserted-by":"crossref","DOI":"10.4161\/onci.27257","article-title":"Human papillomavirus (HPV) deregulation of Toll-like receptor 9","volume":"3","author":"Hasan","year":"2014","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0405","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3892\/or.2014.3142","article-title":"Human papilloma virus, DNA methylation and microRNA expression in cervical cancer (Review)","volume":"31","author":"Jimenez-Wences","year":"2014","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0410","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2353\/ajpath.2008.080280","article-title":"Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins","volume":"173","author":"Krawczyk","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0415","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/1743-422X-7-238","article-title":"High-risk HPV E5-induced cell fusion: a critical initiating event in the early stage of HPV-associated cervical cancer","volume":"7","author":"Gao","year":"2010","journal-title":"Virol. J."},{"issue":"9","key":"10.1016\/bs.acc.2017.01.004_bb0420","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/ijc.22089","article-title":"E5 protein of human papillomavirus 16 downregulates HLA class I and interacts with the heavy chain via its first hydrophobic domain","volume":"119","author":"Ashrafi","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0425","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/JVI.77.5.2819-2831.2003","article-title":"Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation","volume":"77","author":"Fehrmann","year":"2003","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0430","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/JVI.76.1.220-231.2002","article-title":"E5 protein of human papillomavirus type 16 protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis","volume":"76","author":"Zhang","year":"2002","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb0435","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/jvi.69.7.4489-4494.1995","article-title":"Human papillomavirus type 16 E5 protein affects cell-cell communication in an epithelial cell line","volume":"69","author":"Oelze","year":"1995","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb0440","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1128\/JVI.02114-10","article-title":"Human papillomavirus type 16 E5 protein induces expression of beta interferon through interferon regulatory factor 1 in human keratinocytes","volume":"85","author":"Muto","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0445","series-title":"Human Papillomavirus and Related Diseases Report","author":"Bruni","year":"2014"},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0450","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jegh.2013.11.003","article-title":"Prevalence and risk factors of human papillomavirus infection types 16\/18\/45 in a cohort of French females aged 15-23 years","volume":"4","author":"Baudu","year":"2014","journal-title":"J. Epidemiol. Glob. Health"},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0455","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1086\/528379","article-title":"Circumcision and human papillomavirus infection in men: a site-specific comparison","volume":"197","author":"Hernandez","year":"2008","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0460","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ijc.20385","article-title":"Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial","volume":"112","author":"Tokudome","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 5","key":"10.1016\/bs.acc.2017.01.004_bb0465","doi-asserted-by":"crossref","first-page":"F168","DOI":"10.1016\/j.vaccine.2012.06.045","article-title":"Human papillomavirus, human immunodeficiency virus and immunosuppression","volume":"30","author":"Denny","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/bs.acc.2017.01.004_bb0470","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.biopha.2014.12.041","article-title":"Overview of high-risk HPV's 16 and 18 infected cervical cancer: pathogenesis to prevention","volume":"70","author":"Ramakrishnan","year":"2015","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb0475","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0480","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/sj.bjc.6601650","article-title":"A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland","volume":"90","author":"Hinkula","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0485","first-page":"171","article-title":"Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix","volume":"10","author":"Madeleine","year":"2001","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/bs.acc.2017.01.004_bb0490","doi-asserted-by":"crossref","first-page":"847684","DOI":"10.5402\/2011\/847684","article-title":"Smoking and cervical cancer","volume":"2011","author":"Fonseca-Moutinho","year":"2011","journal-title":"ISRN Obstet. Gynecol."},{"issue":"21","key":"10.1016\/bs.acc.2017.01.004_bb0495","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/jnci\/94.21.1604","article-title":"Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer","volume":"94","author":"Smith","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0500","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ijc.20257","article-title":"Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study","volume":"111","author":"Smith","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 5","key":"10.1016\/bs.acc.2017.01.004_bb0505","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0510","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ijc.22357","article-title":"Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies","volume":"120","author":"International Collaboration of Epidemiological Studies of Cervical Cancer","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 10","key":"10.1016\/bs.acc.2017.01.004_bb0515","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","article-title":"Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions","volume":"26","author":"Giuliano","year":"2008","journal-title":"Vaccine"},{"issue":"10 Suppl.","key":"10.1016\/bs.acc.2017.01.004_bb0520","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1002\/cncr.23742","article-title":"Examining the association between socioeconomic status and potential human papillomavirus-associated cancers","volume":"113","author":"Benard","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/bs.acc.2017.01.004_bb0525","series-title":"Human Papillomavirus and Related Diseases report","author":"Bruni","year":"2016"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0530","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1002\/ijc.27397","article-title":"Race and prevalence of human papillomavirus infection among men residing in Brazil, Mexico and the United States","volume":"131","author":"Akogbe","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb0535","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1055-9965.EPI-13-0303","article-title":"Racial differences in the incidence and clearance of human papilloma virus (HPV): the HPV in men (HIM) study","volume":"22","author":"Schabath","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0540","first-page":"3","article-title":"Cervical human papillomavirus infection in a sample of Hispanic women living in Puerto Rico: comparison with cervical cytology reports","volume":"32","author":"Mendez","year":"2013","journal-title":"P. R. Health Sci. J."},{"issue":"10 Suppl.","key":"10.1016\/bs.acc.2017.01.004_bb0545","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/cncr.23757","article-title":"Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States","volume":"113","author":"Wu","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0550","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/AOG.0b013e31826e4609","article-title":"Cervical carcinoma rates among young females in the United States","volume":"120","author":"Benard","year":"2012","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0555","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1055-9965.EPI-10-0645","article-title":"Behavioral\/lifestyle and immunologic factors associated with HPV infection among women older than 45 years","volume":"19","author":"Gonzalez","year":"2010","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0560","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/infdis\/jis660","article-title":"A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States","volume":"207","author":"Gravitt","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0565","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/infdis\/jis662","article-title":"Human papillomavirus in older women: new infection or reactivation?","volume":"207","author":"Brown","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0570","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/AOG.0000000000000171","article-title":"Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population","volume":"123","author":"Sinno","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0575","doi-asserted-by":"crossref","first-page":"480573","DOI":"10.1155\/2014\/480573","article-title":"A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma","volume":"2014","author":"Leonard","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/bs.acc.2017.01.004_bb0580","doi-asserted-by":"crossref","first-page":"812368","DOI":"10.1155\/2011\/812368","article-title":"The strong protective effect of circumcision against cancer of the penis","volume":"2011","author":"Morris","year":"2011","journal-title":"Adv. Urol."},{"issue":"4 Suppl.","key":"10.1016\/bs.acc.2017.01.004_bb0585","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2010.01.010","article-title":"Human papillomavirus-related disease in men: not just a women's issue","volume":"46","author":"Palefsky","year":"2010","journal-title":"J. Adolesc. Health"},{"issue":"11","key":"10.1016\/bs.acc.2017.01.004_bb0590","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3201\/eid1611.100452","article-title":"Oropharyngeal cancer epidemic and human papillomavirus","volume":"16","author":"Ramqvist","year":"2010","journal-title":"Emerg. Infect. Dis."},{"issue":"16","key":"10.1016\/bs.acc.2017.01.004_bb0595","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1001\/jama.287.16.2120","article-title":"2001 Consensus guidelines for the management of women with cervical cytological abnormalities","volume":"287","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0600","first-page":"342","article-title":"American Cancer Society guideline for the early detection of cervical neoplasia and cancer","volume":"52","author":"Saslow","year":"2002","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0605","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"137","author":"Saslow","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0610","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-9378-4-8","article-title":"Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline","volume":"4","author":"Schiffman","year":"2009","journal-title":"Infect. Agent Cancer"},{"key":"10.1016\/bs.acc.2017.01.004_bb0615","series-title":"Hybrid Capture 2 High-Risk HPV DNA Test [Package Insert, 5199-1220]","author":"Digene","year":"2004"},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0620","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jmoldx.2011.09.005","article-title":"Analytical comparison of the cobas HPV test with hybrid capture 2 for the detection of high-risk HPV genotypes","volume":"14","author":"Lindemann","year":"2012","journal-title":"J. Mol. Diagn."},{"issue":"Suppl. 1","key":"10.1016\/bs.acc.2017.01.004_bb0625","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1386-6532(09)70009-5","article-title":"Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions","volume":"45","author":"Dockter","year":"2009","journal-title":"J. Clin. Virol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0630","series-title":"Cervista HPV HR [Package Insert, PRD-00804, Revision 204]","author":"Hologic Inc.","year":"2015"},{"key":"10.1016\/bs.acc.2017.01.004_bb0635","series-title":"Cobas HPV Test [Package Insert, 05641268001, Rev. 1.0]","author":"Roche Molecular Systems Inc.","year":"2010"},{"key":"10.1016\/bs.acc.2017.01.004_bb0640","series-title":"Gen-Probe, Aptima HPV Assay [Package Insert, 50218EN, Rev. A]","year":"2001"},{"issue":"Suppl. 3","key":"10.1016\/bs.acc.2017.01.004_bb0645","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S1386-6532(02)00187-7","article-title":"Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail","volume":"25","author":"Poljak","year":"2002","journal-title":"J. Clin. Virol."},{"issue":"1\u20132","key":"10.1016\/bs.acc.2017.01.004_bb0650","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jviromet.2005.12.004","article-title":"Resolving repeatedly borderline results of Hybrid Capture 2 HPV DNA test using polymerase chain reaction and genotyping","volume":"134","author":"Seme","year":"2006","journal-title":"J. Virol. Methods"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0655","first-page":"147","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0660","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0002-9378(03)00413-7","article-title":"A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations","volume":"188","author":"The ASCUS-LSIL Triage Study (ALTS) Group","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0665","doi-asserted-by":"crossref","first-page":"62.e1","DOI":"10.1016\/j.ajog.2014.06.057","article-title":"Adherence to the 2012 national cervical cancer screening guidelines: a pilot study","volume":"212","author":"Teoh","year":"2015","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0670","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0675","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000001263","article-title":"Practice Bulletin No. 157: cervical cancer screening and prevention. American College of Obstetricians and Gynecologist","volume":"127","year":"2016","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0680","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","article-title":"Screening for cervical cancer: US Preventive Services Task Force recommendation statement","volume":"156","author":"Moyer","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2017.01.004_bb0685","series-title":"Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force","author":"Kulasingam","year":"2011"},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0690","doi-asserted-by":"crossref","first-page":"851","DOI":"10.7326\/M14-2426","article-title":"Cervical cancer screening in average-risk women: best practice advice from the Clinical Guidelines Committee of the American College of Physicians","volume":"162","author":"Sawaya","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.acc.2017.01.004_bb0695","series-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology","article-title":"Cervical Cancer Screening","author":"Partridge","year":"2012"},{"key":"10.1016\/bs.acc.2017.01.004_bb0700","unstructured":"N. Broutet, et al., Comprehensive Cervical Cancer Control: A Guide to Essential Practice, WHO, Geneva, Sweden, 2014"},{"key":"10.1016\/bs.acc.2017.01.004_bb0705","first-page":"1","article-title":"Screening for cervical cancer. Clinical management guidelines for obstetricians-gynecologist","volume":"131","author":"American College of Gynecologist and Obstetricians","year":"2012","journal-title":"Pract. Bull."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0710","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/01.AOG.0000460763.59152.9e","article-title":"Committee Opinion No, 624: cervical cancer screening in low-resource settings","volume":"125","author":"American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women","year":"2015","journal-title":"Obstet. Gynecol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0715","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.AOG.0000296488.85807.b3","article-title":"Liquid compared with conventional cervical cytology: a systematic review and meta-analysis","volume":"111","author":"Arbyn","year":"2008","journal-title":"Obstet. Gynecol."},{"issue":"16","key":"10.1016\/bs.acc.2017.01.004_bb0720","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.2009.1569","article-title":"Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial","volume":"302","author":"Siebers","year":"2009","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/bs.acc.2017.01.004_bb0725","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/archinte.168.17.1881","article-title":"Trade-offs in cervical cancer prevention: balancing benefits and risks","volume":"168","author":"Stout","year":"2008","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0730","first-page":"29","article-title":"Screening interval and risk of invasive squamous cell cervical cancer","volume":"101","author":"Miller","year":"2003","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/bs.acc.2017.01.004_bb0735","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb0740","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/bs.acc.2017.01.004_bb0745","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa071430","article-title":"Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer","volume":"357","author":"Mayrand","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0750","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"9916","key":"10.1016\/bs.acc.2017.01.004_bb0755","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb0760","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/annonc\/mdp471","article-title":"European guidelines for quality assurance in cervical cancer screening\u2014summary document","volume":"21","author":"Arbyn","year":"2010","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0765","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(11)70296-0","article-title":"Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial","volume":"13","author":"Rijkaart","year":"2012","journal-title":"Lancet Oncol."},{"issue":"51","key":"10.1016\/bs.acc.2017.01.004_bb0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta13510","article-title":"ARTISTIC: a randomised trial of-human-papillomavirus (HPV) testing in primary cervical screening","volume":"13","author":"Kitchener","year":"2009","journal-title":"Health Technol. Assess."},{"issue":"16","key":"10.1016\/bs.acc.2017.01.004_bb0775","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa073204","article-title":"Human papillomavirus and Papanicolaou tests to screen for cervical cancer","volume":"357","author":"Naucler","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0780","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejca.2011.01.008","article-title":"A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial","volume":"47","author":"Kitchener","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"5 Suppl. 1","key":"10.1016\/bs.acc.2017.01.004_bb0785","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1097\/LGT.0b013e31828543c5","article-title":"Five-year risk of recurrence following treatment of CIN2, CIN3, or AIS: performance of HPV and Pap cotesting in post-treatment management","volume":"17","author":"Katki","year":"2013","journal-title":"J. Low. Genit. Tract Dis."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0790","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ygyno.2007.03.016","article-title":"Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix","volume":"106","author":"Costa","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb0795","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-148-7-200804010-00004","article-title":"Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003\u20132005","volume":"148","author":"Datta","year":"2008","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0800","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.AOG.0000120143.50098.c7","article-title":"Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more","volume":"103","author":"Goldie","year":"2004","journal-title":"Obstet. Gynecol."},{"issue":"11","key":"10.1016\/bs.acc.2017.01.004_bb0805","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1532-5415.2001.4911243.x","article-title":"Advancing age and cervical cancer screening and prognosis","volume":"49","author":"Sawaya","year":"2001","journal-title":"J. Am. Geriatr. Soc."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0810","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/j.1471-0528.2006.01099.x","article-title":"Vaginal vault smears after hysterectomy for reasons other than malignancy: a systematic review of the literature","volume":"113","author":"Stokes-Lampard","year":"2006","journal-title":"BJOG"},{"issue":"21","key":"10.1016\/bs.acc.2017.01.004_bb0815","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJM199611213352103","article-title":"Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease","volume":"335","author":"Pearce","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0820","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ogc.2013.02.005","article-title":"Cervical cancer screening in immunocompromised women","volume":"40","author":"Nguyen","year":"2013","journal-title":"Obstet. Gynecol. Clin. North Am."},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0825","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAI.0b013e31828177d7","article-title":"Invasive cervical cancer risk among HIV-infected women: a North American multi-cohort collaboration prospective study","volume":"62","author":"Abraham","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"11","key":"10.1016\/bs.acc.2017.01.004_bb0830","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1002\/ijc.22947","article-title":"Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women","volume":"121","author":"Kitchener","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0835","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/AOG.0b013e31826a8bbd","article-title":"Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus","volume":"120","author":"Massad","year":"2012","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0840","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.293.12.1471","article-title":"Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results","volume":"293","author":"Harris","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0845","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.ackd.2013.07.003","article-title":"Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening","volume":"21","author":"Asch","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb0850","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/annrheumdis-2013-204993","article-title":"Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb0855","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","article-title":"Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature","volume":"13","author":"Zard","year":"2014","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0860","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"14","key":"10.1016\/bs.acc.2017.01.004_bb0865","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa0808516","article-title":"HPV screening for cervical cancer in rural India","volume":"360","author":"Sankaranarayanan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2017.01.004_bb0870","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/jnci\/djq342","article-title":"Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial","volume":"102","author":"Denny","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0875","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/cncy.21544","article-title":"Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices","volume":"123","author":"Blatt","year":"2015","journal-title":"Cancer Cytopathol."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0880","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cncy.21632","article-title":"The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital","volume":"124","author":"Choi","year":"2016","journal-title":"Cancer Cytopathol."},{"issue":"8","key":"10.1016\/bs.acc.2017.01.004_bb0885","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7326\/M15-0420","article-title":"Inefficiencies and high-value improvements in US cervical cancer screening practice: a cost-effectiveness analysis","volume":"163","author":"Kim","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0890","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.vaccine.2015.12.063","article-title":"Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines","volume":"34","author":"Van Damme","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb0895","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","article-title":"Aluminium compounds for use in vaccines","volume":"82","author":"Lindblad","year":"2004","journal-title":"Immunol. Cell Biol."},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb0900","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J. Immunol."},{"issue":"Suppl. 10","key":"10.1016\/bs.acc.2017.01.004_bb0905","doi-asserted-by":"crossref","first-page":"K62","DOI":"10.1016\/j.vaccine.2008.05.066","article-title":"Immunobiology of human papillomavirus infection and vaccination\u2014implications for second generation vaccines","volume":"26","author":"Stanley","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb0910","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb0915","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1447-0756.2009.01167.x","article-title":"Immunogenicity and safety of human papillomavirus-16\/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women","volume":"36","author":"Bhatla","year":"2010","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb0920","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4161\/hv.7.2.13948","article-title":"The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay","volume":"7","author":"Brown","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0925","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4161\/hv.7.12.18281","article-title":"Comparative immunogenicity and safety of human papillomavirus (HPV)-16\/18 vaccine and HPV-6\/11\/16\/18 vaccine: follow-up from months 12-24 in a phase III randomized study of healthy women aged 18-45 years","volume":"7","author":"Einstein","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"52","key":"10.1016\/bs.acc.2017.01.004_bb0930","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"issue":"Suppl. 5","key":"10.1016\/bs.acc.2017.01.004_bb0935","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb0940","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccin."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb0945","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.4161\/hv.36121","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a phase III randomized trial","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb0950","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/INF.0000000000000694","article-title":"An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age","volume":"34","author":"Kosalaraksa","year":"2015","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"21","key":"10.1016\/bs.acc.2017.01.004_bb0955","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"41","key":"10.1016\/bs.acc.2017.01.004_bb0960","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1016\/j.vaccine.2009.07.027","article-title":"Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine","volume":"27","author":"Rowhani-Rahbar","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl. 3","key":"10.1016\/bs.acc.2017.01.004_bb0965","article-title":"Chapter 13: current findings from prophylactic HPV vaccine trials","volume":"24","author":"Koutsky","year":"2006","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/bs.acc.2017.01.004_bb0970","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Group","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9580","key":"10.1016\/bs.acc.2017.01.004_bb0975","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/bs.acc.2017.01.004_bb0980","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"37","key":"10.1016\/bs.acc.2017.01.004_bb0985","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/bs.acc.2017.01.004_bb0990","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9679","key":"10.1016\/bs.acc.2017.01.004_bb0995","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/bs.acc.2017.01.004_bb1000","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(11)70213-3","article-title":"Efficacy of a bivalent HPV 16\/18 vaccine against anal HPV 16\/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial","volume":"12","author":"Kreimer","year":"2011","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb1005","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiu357","article-title":"Reduced prevalence of vulvar HPV16\/18 infection among women who received the HPV16\/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial","volume":"210","author":"Lang Kuhs","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb1010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb1015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"42","key":"10.1016\/bs.acc.2017.01.004_bb1020","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1016\/j.vaccine.2015.08.072","article-title":"Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)\u2014The MAM Study","volume":"33","author":"Giuliano","year":"2015","journal-title":"Vaccine"},{"issue":"17","key":"10.1016\/bs.acc.2017.01.004_bb1025","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb1030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.vaccine.2013.11.059","article-title":"Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16\/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months","volume":"32","author":"Lazcano-Ponce","year":"2014","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb1035","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.4161\/hv.7.12.18322","article-title":"Immunogenicity and safety of the HPV-16\/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study","volume":"7","author":"Romanowski","year":"2011","journal-title":"Hum. Vaccin."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb1040","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb1045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/bs.acc.2017.01.004_bb1050","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/bs.acc.2017.01.004_bb1055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/1753-6405.12372","article-title":"Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators","volume":"39","author":"Barbaro","year":"2015","journal-title":"Aust. N. Z. J. Public Health"},{"key":"10.1016\/bs.acc.2017.01.004_bb1060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med."},{"key":"10.1016\/bs.acc.2017.01.004_bb1065","doi-asserted-by":"crossref","first-page":"g7584","DOI":"10.1136\/bmj.g7584","article-title":"Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model","volume":"350","author":"Jit","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/bs.acc.2017.01.004_bb1070","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1542\/peds.2014-4199","article-title":"Coadministration of a 9-valent human papillomavirus vaccine with meningococcal and Tdap vaccines","volume":"136","author":"Schilling","year":"2015","journal-title":"Pediatrics"},{"issue":"29","key":"10.1016\/bs.acc.2017.01.004_bb1075","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6429a3","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years\u2014United States, 2014","volume":"64","author":"Reagan-Steiner","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"13","key":"10.1016\/bs.acc.2017.01.004_bb1080","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.vaccine.2015.01.084","article-title":"Reduction in HPV 16\/18-associated high grade cervical lesions following HPV vaccine introduction in the United States\u20142008\u20132012","volume":"33","author":"Hariri","year":"2015","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/bs.acc.2017.01.004_bb1085","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.vaccine.2016.02.022","article-title":"HPV vaccine: less is more","volume":"34","author":"Caskey","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/bs.acc.2017.01.004_bb1090","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2009.04.005","article-title":"The impact of human papillomavirus vaccination on cervical cancer prevention efforts","volume":"114","author":"Massad","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/bs.acc.2017.01.004_bb1095","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.arcmed.2009.06.003","article-title":"The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change","volume":"40","author":"Franco","year":"2009","journal-title":"Arch. Med. Res."},{"issue":"9783","key":"10.1016\/bs.acc.2017.01.004_bb1100","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/S0140-6736(11)60551-5","article-title":"Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study","volume":"377","author":"Brotherton","year":"2011","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/bs.acc.2017.01.004_bb1105","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/infdis\/jis590","article-title":"Fall in human papillomavirus prevalence following a national vaccination program","volume":"206","author":"Tabrizi","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"10","key":"10.1016\/bs.acc.2017.01.004_bb1110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","article-title":"Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study","volume":"14","author":"Tabrizi","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb1115","first-page":"915","article-title":"Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program","volume":"25","author":"Baldur-Felskov","year":"2014","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/bs.acc.2017.01.004_bb1120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/cid\/cit436","article-title":"Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark","volume":"57","author":"Blomberg","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2017.01.004_bb1125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vaccine.2013.10.085","article-title":"Reduction in HPV 16\/18 prevalence in sexually active young women following the introduction of HPV immunisation in England","volume":"32","author":"Mesher","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/bs.acc.2017.01.004_bb1130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5694\/mja15.01038","article-title":"HPV vaccine impact in Australian women: ready for an HPV-based screening program","volume":"204","author":"Brotherton","year":"2016","journal-title":"Med. J. Aust."},{"issue":"12","key":"10.1016\/bs.acc.2017.01.004_bb1135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11864-015-0373-1","article-title":"Making sense of cervical cancer screening guidelines and recommendations","volume":"16","author":"Davis","year":"2015","journal-title":"Curr. Treat. Options Oncol."}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242317300045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242317300045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:34:41Z","timestamp":1758742481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242317300045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128120743"],"references-count":227,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2017.01.004","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}